MAPT and Alzheimer disease: In particular, in the case of AD and MCI, recent studies have focused on detection of individual blood biomarkers, including Aβ and phosphorylated tau proteins (pTau181 and pTau217), and on correlation of these findings with elevated levels of these proteins in CSF and increased tau PET and amyloid PET uptake24,38–42,55,56.